REG - Proteome Sciences - Annual General Meeting Statement

Proteome SciencesAnnouncement

14/05/2026 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260514:nRSN3451Ea&default-theme=true

RNS Number : 3451E  Proteome Sciences PLC  14 May 2026

 

14 May 2026

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting Statement

 

At the Company's Annual General Meeting ("AGM") being held today at 12.00
noon, the Chairman, Christopher Pearce, made the following statement:

 

"Good progress is being made in order levels in our services business and the
recovery that we hoped for in TMT and reagent sales continues in the first
half following the cuts in US NIH budgets and academic grants in 2025.

With the significant investment made in the business over the last 2 years, we
believe we are well positioned to deliver substantial returns from our
activities in the fast growing field of proteomics."

- Ends -

For further information:

 Proteome Sciences plc
 Christopher Pearce, Executive Chairman
 Dr. Ian Pike, Chief Scientific Officer                               Tel: +44 (0)20 7043 2116
 Richard Dennis, Chief Commercial Officer

 SP Angel Corporate Finance LLP  (Nominated Adviser & Broker)
 David Hignell/Richard Morrison/Josh Ray  (Corporate Finance)         Tel: +44 (0) 20 3470 0470

 Vadim Alexandre (Corporate Broking)

 

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

 

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and
contextualising new targets and defining mechanisms of biological activity,
with analysis using a range of depletion strategies in combination
with TMTcalibrator™ providing access to over 8,500 circulating plasma
proteins for the discovery of disease-related biomarkers. Chemoproteomics
using Solvent Shift  reveals the selectivity that drugs have to binding one
or more proteins in the sample proteome.  Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free biomarker
analyses in situations where standard ELISA assays are not available.

Further information on the Company can be found on its website at:
https://www.proteomics.com/ (https://www.proteomics.com/)

The Company's LEI is 213800Q62ICXANKU2986.

This announcement should be read in its entirety. In particular, the
information in the "Important Notices" section of the announcement should be
read and understood.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMEAPSLFFPKEEA



            Copyright 2019 Regulatory News Service, all rights reserved